Provided by Tiger Trade Technology Pte. Ltd.

Meiragtx Holdings Plc

8.65
+0.05000.58%
Post-market: 8.650.00000.00%18:56 EST
Volume:510.74K
Turnover:4.40M
Market Cap:696.25M
PE:-4.10
High:8.72
Open:8.59
Low:8.45
Close:8.60
52wk High:9.73
52wk Low:4.55
Shares:80.49M
Float Shares:31.70M
Volume Ratio:1.01
T/O Rate:1.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1103
EPS(LYR):-2.1167
ROE:-611.42%
ROA:-41.91%
PB:-17.17
PE(LYR):-4.09

Loading ...

MeiraGTx Announces Strategic Collaboration with Eli Lilly for Ophthalmology Gene Therapies

Reuters
·
Nov 10

MeiraGTx Enters Into Strategic Collaboration With Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

THOMSON REUTERS
·
Nov 10

MeiraGTx Holdings Plc - to Receive $75 Mln Upfront and $400 Mln in Milestones

THOMSON REUTERS
·
Nov 10

MeiraGTx Holdings Plc - Grants Lilly Exclusive Rights to Aav-Aipl1 Program

THOMSON REUTERS
·
Nov 10

MeiraGTx Holdings PLC expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
Nov 07

MeiraGTx Holdings (NASDAQ:MGTX) Is Making Moderate Use Of Debt

Simply Wall St.
·
Oct 22

MeiraGTx CFO & COO Richard Giroux Reports Disposal of Common Shares

Reuters
·
Oct 22

MeiraGTx initiated with a Strong Buy at Raymond James

TIPRANKS
·
Oct 21

MeiraGTx Holdings plc President & CEO Alexandria Forbes Reports Disposal of Common Shares

Reuters
·
Oct 08

BRIEF-MeiraGTx Announces Two Posters At The European Society Of Gene And Cell Therapy (ESGCT) 2025 Annual Congress

Reuters
·
Oct 07

MeiraGTx Announces Promising New Clinical Study on Novel AAV Gene Therapy Capsids for Ocular Diseases at ESGCT 2025

Reuters
·
Oct 07

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (Esgct) 2025 Annual Congress

THOMSON REUTERS
·
Oct 07

Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations to Drive Next Phase of Growth

Reuters
·
Oct 02

MeiraGTx Holdings Is Maintained at Buy by Chardan Capital

Dow Jones
·
Aug 15

RBC Capital Adjusts Price Target on MeiraGTx to $12 From $13, Maintains Outperform Speculative Rating

MT Newswires Live
·
Aug 15

MeiraGTx Hldgs Q2 EPS $(0.48) Misses $(0.46) Estimate, Sales $3.691M Miss $8.003M Estimate

Benzinga
·
Aug 14

MeiraGTx Secures RMAT Designation from FDA for AAV-GAD in Parkinson's Treatment, Aligns with FDA on Phase 2 Study for Radiation-Induced Xerostomia

Reuters
·
Aug 14

BRIEF-MeiraGTx Q2 EPS USD -0.48

Reuters
·
Aug 14

MeiraGTx Q2 Operating Expenses USD 48.484 Million

THOMSON REUTERS
·
Aug 14

MeiraGTx Q2 Income From Operations USD -44.793 Million

THOMSON REUTERS
·
Aug 14